- Medical news articles blogs and discussions Home » Upcoming News » Paediatrics
-
Sort Paediatrics by:
Newest |
Oldest |
Most Popular |
Least Popular |
Abbott announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), granted a positive opinion recommending approval of HUMIRA(R) (adalimumab) for the treatment of severe Crohn's disease. HUMIRA will be the first
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
A study led by Mayo Clinic found that adalimumab (HUMIRA®)) is an effective treatment for adults with Crohn's disease who do not respond to infliximab (REMICADE®) therapy. These findings were published online by Annals of Internal Medicine.Crohn's disease is an inflammatory disorder of the gastroin
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Crohn's disease is a chronic relapsing inflammatory disorder of the intestinal tract that affects an estimated 0.15% of people in the developedworld. Common symptoms include abdominal pain and diarrhea, but the disorder is often associated with debilitating clinical complications. Researchersfrom t
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
UCB announced today that new data presented at Digestive Disease Week 2007 (DDW) demonstrated long-term response and remission in Crohn's disease patients treated with CIMZIA(TM) (certolizumab pegol), the only Fc-free PEGylated, Fab' fragment anti-TNF. The study, called PRECiSE 3 (P3), is a long
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Abbott today announced results from a post-hoc analysis of a pivotal study presented at the Digestive Disease Week annual meeting in Washington, D.C. showing patients with moderate to severely active Crohn's disease treated with HUMIRA® (adalimumab) maintenance therapy were almost 60 percent less l
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
In the largest ever study published to date, a consortium of UK scientists has discovered over 20 genes and regions of the human genome that contribute to diseases such as diabetes, rheumatoid arthritis and coronary heart disease.The Wellcome Trust Control Consortium's 9 million pound study is a co
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission has approved a new indication for REMICADE(R) (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in pediatric patients aged 6 to 17 years, who have not responded to
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA® (adalimumab) as a treatment for severe Crohn's disease. HUMIRA is the first self-administered biologic for the treatment of Crohn's disease and offers an effective and convenient
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
The European Commission (EC) has approved a new indication for Remicade® (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in paediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primar
read more »
Source:http://www.medicalnewstoday.com
Discuss Bury
Source:http://www.medicalnewstoday.com
Discuss Bury
Medinews is an online community dedicated for promoting and discussing latest medical news, research articles and blogs. You can also find regular updates on health news for discussion by health professionals.
